菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Services for mRNA products

The messenger RNA (mRNA) product class that stems from our microbial production system provides a single-source service for plasmid DNA (pDNA) manufacturing through drug substance (DS) and drug product (DP) production. An expert, well-trained team complements a leading quality system to ensure GMP compatibility.

The service optimizes sequences and process development, encompassing E. coli fermentation, cell lysis, and purification for pDNA; in vitro transcription (IVT) with co-capping and post-capping options and mRNA purification; and encapsulation, ultrafiltration/diafiltration (UF/DF), and fill and finish for LNP. Other key features include seamless technical transfer and effortless scale-up, comprehensive analytical development and quality control (QC) testing, and full CMC and regulatory support.

Contact Us

Key Features

Rapid timeline

From DNA sequence to IND filing, our mRNA project timelines are exceptionally fast without sacrificing the flexibility needed to achieve your goals. A timeline of only 8 months covers all critical CMC processes.


Diverse modalities

From pDNA to decorated mRNA-LNP, our mRNA product class supports a variety of biologics products.

WuXi Biologics is well-equipped for GMP production of DS. To enable scalable pDNA production, our manufacturing facility features a fermenter with capacity that scales up to 300 L. A diversity of vessel volumes and purification equipment support similarly scalable mRNA transcription and purification while increasing the yield.

Separate suites for pDNA linearization, mRNA synthesis, and mRNA purification protect against cross-contamination. In particular, the mRNA purification suite capitalizes on the latest single-use technology. An efficient sequence-to-cell bank process complements an equally streamlined mRNA production process to prepare for DP.

Both DP stages, development and manufacturing, benefit from state-of-the art mRNA-LNP drug development systems and aseptic filling systems. Powered by robotics, the aseptic filling systems minimize hands-on time, and the risks associated with manual systems.

DP development includes formulation development, process development, and technology transfer and features the following technology:

  • Microfluidic and T-junction mixing
  • Lyophilization cycle development
  • Feasability and pilot scale of 25 µL to 10 L
  • Particle size, PDI, encapsulation rate, potency, and more characterization techniques

DP manufacturing features the following technology:

  • Two segregated filling lines
  • Microfluidic and T-junction encapsulation
  • Aseptic formulation isolator
  • Single-use systems
  • Ready-to-use (RTU) container closure systems (CCS), including vials and prefilled syringes (PFS)

A dedicated team of well-trained and experienced professionals improves product quality and safety and ensures regulatory compliance.

  • Integrated laboratories support diverse mRNA modalities
  • Methods development, transfer, and qualification and validation
  • Product biochemical, biophysical, and biological characterization and comparability analysis
  • Comprehensive analytical capabilities that deliver full CMC packages to enable IND and BLA filings
  • Tox/clinical lot release and stability testing for DS and DP
  • Generation, qualification, characterization, storage, and lifetime management of a reference standard
  • Analytical investigation and troubleshooting for issues related to GMP manufacturing

WuXi Biologics has an ingrained commitment to quality. Our global quality system, QC, and operational systems are well-established and meet or exceed standards set by the FDA, EMA, NMPA, and other major regulatory agencies worldwide

We have harmonized our quality assurance (QA) and quality management system across all global sites. This approach maximizes efficiency and quality for confidence in the clinical and commercial production of DS and DP, both biologic and vaccine.

Connect with our Experts

Let’s discuss your project needs.
Contact Us